You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.
MyHeritage plans to offer Promethease free of charge through the end of this year and to maintain SNPedia as a free resource for academic and non-profit users.
By sequencing an Indus Valley Civilization representative and related individuals, investigators learned more about the South Asian ancestry, farming history, and languages.
In an abstract to be presented at ASHG, Baylor Genetics researchers will discuss how Emedgene's AI-driven platform helped them streamline and standardize sequencing review.
Researchers identified tumor microbe and immune differences in tumor samples from pancreatic ductal adenocarcinoma patients with exceptionally long survival.
In PNAS this week: intronic STAT3 splice site linked to autosomal dominant primary immunodeficiency condition, human B lymphocyte changes following Epstein-Barr virus exposure, and more.
The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
In PLOS this week: alternatively spliced form of FBXO38 contributes to chronic obstructive pulmonary disease, evolution of the avian influenza virus H9N2, and more.
By sequencing 10 Bronze, early Iron, and late Iron Age individuals, researchers retraced ancestry patterns at a Philistine port city in present-day Israel.
At the WIN Symposium, a researcher from Sheba Medical Center discussed ongoing efforts to develop a 22-gene signature for predicting brain metastasis in NSCLC.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.